Maternal Docosahexaenoic Acid Supplementation and Bronchopulmonary Dysplasia in Infants

To the Editor In the Maternal Omega-3 Supplementation to Reduce Bronchopulmonary Dysplasia in Very Preterm Infants (MOBYDIck) trial, Dr Marc and colleagues reported no difference in bronchopulmonary dysplasia –free survival but higher rates for bronchopulmonary dysplasia in premature infants whose breastfeeding mothers received docosahexaenoic acid (DHA) supplementation vs placebo. A similar increase in rates for bronchopulmonary dysplasia also was reported in the N3RO trial, in which DHA supplementati on or placebo was directly administered to premature infants. We would like to suggest a pathophysiological explanation for the findings that might help in designing future trials. Furthermore, to investigate the robustness of the findings in the MOBYDIck trial, we propose performing an additional s tratified statistical analysis.
Source: JAMA - Category: General Medicine Source Type: research